Observing Effectiveness of Subcutaneous Anifrolumab for Adults with Systemic Lupus Erythematosus in Routine Care

What this Trial Is About

Researchers are evaluating the real-world clinical outcomes and patient-reported experiences of adults with systemic lupus erythematosus SLE who start treatment with subcutaneous anifrolumab. This prospective, single-arm, multicenter, non-interventional study focuses on patients who have not previously used anifrolumab subcutaneously or intravenously. The study aims to describe disease activity, including remission and lupus low disease activity states, quality of life, medication patterns, flares, and organ damage over time. Participants will receive subcutaneous anifrolumab as part of their routine care, with treatment decisions made independently of the study. The study follows patients for 24 months to capture long-term disease control, medication use, and organ damage progression. Data collected include clinical assessments and patient-reported outcomes in a real-life setting without altering usual treatment. During the 24-month observation period, participants will be evaluated at routine visits where disease activity, treatment patterns, quality of life, fatigue, flares, and organ damage are measured. Researchers will review outcomes such as remission rates, time to remission, and sustained disease control. Patient questionnaires and clinical assessments will help track these measures, providing insights into long-term disease management and treatment effects in everyday practice.

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care